drugset / Trial / NCT07107074

Effects of a Widely Used Vaccine Adjuvant in Subjects With Early Alzheimer's Disease Double-blind Study to Assess the Safety and Efficacy of AD04 in Patients With Early Alzheimer's Disease - ADVANCE

NCT07107074 ↗

Phase 2 Active not recruiting 122 enrolled ADvantage Therapeutics
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this randomized, placebo-controlled phase 2b study is to prospectively evaluate AD04's potential as a disease-modifying drug in AD. By evaluating the safety, pharmacodynamics, and efficacy of AD04 in early AD patients, we aim to deliver a comprehensive and robust data set that furthers our understanding of the effects of AD04 in AD pathology.

Timeline

Start
2023-11-08
Primary completion
2026-12
Completion
2027-07

Drugs

EvaluationDrugModalityDoseRoute
Subject AD04 Unknown 1 ml Subcutaneous